問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (非在職)

Division of Urology

Kuang Tien General Hospital (在職)

Division of Urology

Division of Hematology & Oncology

童綜合醫療社團法人童綜合醫院

Division of Hematology & Oncology

Division of Urology

更新時間:2023-09-19

歐宴泉
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

50Cases

2010-09-30 - 2013-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-12-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-09-30 - 2014-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2013-11-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-01-02 - 2016-06-30

Phase III

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/RPX7009) Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults
  • Condition/Disease

    Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults

  • Test Drug

    Carbavance(meropenem/RPX7009)

Participate Sites
4Sites

Terminated4Sites

2017-11-01 - 2022-12-31

Phase I/II

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After, or are Refractory to Standard Therapy.
  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cell Carcinoma

  • Test Drug

    Vofatamab (B-701)

Participate Sites
9Sites

Terminated8Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2010-11-01 - 2018-06-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-06-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-10-31 - 2010-06-15

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2 3 4 5